Merrimack Pharmaceuticals competitive analysis

Explore Merrimack Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
May 3, 2017Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan1
Jan 11, 2017Liposomes Useful For Drug Delivery1
Jan 14, 2015Use Of Erbb3 Inhibitors In The Treatment Of Triple Negative And Basal-Like Breast Cancers1

Latest PTAB cases involving Merrimack Pharmaceuticals

Discover the latest PTAB cases involving Merrimack Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Merrimack Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MERRIMACK PHARMACEUTICALS - 3 - -
DAIICHI SANKYO11337
TEVA PHARMACEUTICAL INDUSTRIES LTD2727 - -
TEVA PHARMACEUTICALS INC.2 - - -